Movatterモバイル変換

Jump to content

Nifekalant

From Wikipedia, the free encyclopedia

Chemical compound

Pharmaceutical compound

Nifekalant
Clinical data

AHFS/Drugs.com	International Drug Names
Routes of administration	IV
ATC code	none
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name 6-[(2-{(2-hydroxyethyl)[3-(4-nitrophenyl)propyl]amino}ethyl)amino]-1,3-dimethylpyrimidine-2,4(1H,3H)-dione
CAS Number	130636-43-0^Y
PubChemCID	4486
ChemSpider	4331
UNII	5VZ7GZM43E
CompTox Dashboard(EPA)	DTXSID7048374
Chemical and physical data
Formula	C₁₉H₂₇N₅O₅
Molar mass	405.455 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES Cn1c(NCCN(CCO)CCCc2ccc([N+](=O)[O-])cc2)cc(=O)n(C)c1=O
InChI InChI=1S/C19H27N5O5/c1-21-17(14-18(26)22(2)19(21)27)20-9-11-23(12-13-25)10-3-4-15-5-7-16(8-6-15)24(28)29/h5-8,14,20,25H,3-4,9-13H2,1-2H3 Key:OEBPANQZQGQPHF-UHFFFAOYSA-N
(verify)

Nifekalant (INN) is a class IIIantiarrhythmic agent approved inJapan for the treatment of arrhythmias andventricular tachycardia.^[1] It has the brand nameShinbit.

References

^Oyabe A, Sano H (February 2002)."Pharmacological and clinical profile of nifekalant (shinbit injection), a class III antiarrhythmic drug".Nippon Yakurigaku Zasshi.119 (2):103–9.doi:10.1254/fpj.119.103.PMID 11862758.

v
t
e

Ion channel modulators

VDCCsTooltip Voltage-dependent calcium channels

R-type-selective:SNX-482

L-type-selective:Bay K8644

VGKCsTooltip Voltage-gated potassium channels

KCNQ (K_v7)-specific:Flupirtine
Retigabine

IRKsTooltip Inwardly rectifying potassium channel

K_ATPTooltip ATP-sensitive potassium channel-specific:Acetohexamide
Carbutamide
Chlorpropamide
Glibenclamide (glyburide)
Glibornuride
Glicaramide
Gliclazide
Glimepiride
Glipizide
Gliquidone
Glisoxepide
Glyclopyramide
Glycyclamide
Metahexamide
Mitiglinide
Nateglinide
Repaglinide
Tolazamide
Tolbutamide

GIRKTooltip G protein-coupled inwardly rectifying potassium channel-specific:Barium
Caramiphen
Cloperastine
Clozapine
Dextromethorphan
Ethosuximide
Ifenprodil
Tertiapin
Tipepidine

K_ATPTooltip ATP-sensitive potassium channel-specific:Aprikalim
Bimakalim
Cromakalim
Diazoxide
Emakalim
Levcromakalim
Mazokalim
Minoxidil
Minoxidil sulfate
Naminidil
Nicorandil
Pinacidil
Rilmakalim
Sarakalim

GIRKTooltip G protein-coupled inwardly rectifying potassium channel-specific:ML-297 (VU0456810)

K_CaTooltip Calcium-activated potassium channel

Blockers	BK_Ca-specific:Ethanol (alcohol) GAL-021
Activators	BK_Ca-specific:Flufenamic acid Meclofenamic acid Niflumic acid Nimesulide Rottlerin (mallotoxin) Tolfenamic acid

K2PsTooltip Tandem pore domain potassium channel

Blockers	12-O-Tetradecanoylphorbol-13-acetate Arachidonic acid Fluoxetine Norfluoxetine
Activators	Riluzole

VGSCsTooltip Voltage-gated sodium channels

Antianginals:Ranolazine

Aconitine
Atracotoxins (ω-Atracotoxin,Robustoxin,Versutoxin)
Batrachotoxin
Ciguatoxins
Grayanotoxins
Poneratoxin

ENaCTooltip Epithelial sodium channel

Blockers	Amiloride Benzamil Triamterene
Activators	Solnatide

ASICsTooltip Acid-sensing ion channel

Blockers	A-317567 Amiloride Aspirin Ibuprofen PcTX1

CaCCsTooltip Calcium-activated chloride channel

Blockers	Crofelemer DIDS Ethacrynic acid Flufenamic acid Fluoxetine Furosemide Glibenclamide Mefloquine Mibefradil Niflumic acid
Activators	Carbachol

CFTRTooltip Cystic fibrosis transmembrane conductance regulator

Blockers	Glibenclamide Lonidamine Piretanide
Activators	1,7-Phenanthroline 1,10-Phenanthroline 4,7-Phenanthroline 7,8-Benzoquinoline Ivacaftor Phenanthridine

Unsorted

Blockers	Bumetanide Flufenamic acid Meclofenamic acid Mefenamic acid Mepacrine Niflumic acid Talniflumate Tolfenamic acid Trifluoperazine

Others

TRPsTooltip Transient receptor potential channels	Seehere instead.
LGICsTooltip Ligand gated ion channels	Seehere instead.

See also:Receptor/signaling modulators •Transient receptor potential channel modulators

v
t
e

Antiarrhythmic agents (C01B)

Channel blockers

class I
(Na⁺ channel blockers)

class Ia (Phase 0→ andPhase 3→)	Ajmaline Disopyramide Hydroquinidine Lorajmine Prajmaline Procainamide^# Quinidine^# Sparteine
class Ib (Phase 3←)	IV Lidocaine^# enteral Aprindine Mexiletine Tocainide
class Ic (Phase 0→)	Encainide^‡ Ethacizine Flecainide Indecainide^‡ Lorcainide Moracizine^‡ Propafenone

class III
(Phase 3→,K⁺ channel blockers)

class IV
(Phase 4→,Ca²⁺ channel blockers)

Receptor agonists
andantagonists

class II (Phase 4→,β blockers)	Nadolol Pindolol Propranolol cardioselective Acebutolol Atenolol Esmolol Landiolol Metoprolol
A₁ agonist	Adenosine Benzodiazepines Barbiturates
M₂	muscarinic antagonist:Atropine Disopyramide Quinidine muscarinic agonist:Digoxin
α receptors	Amiodarone Bretylium Quinidine Verapamil

Ion transporters

Na⁺/ K⁺-ATPase	Digitoxin Digoxin Ouabain

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byexpanding it.

v
t
e

Retrieved from "https://en.wikipedia.org/w/index.php?title=Nifekalant&oldid=1248582784"

Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp